{"web_url": "http://www.nytimes.com/2016/01/21/business/dealbook/congress-subpoenas-martin-shkreli-over-drug-prices.html", "snippet": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "multimedia": [{"height": 126, "subtype": "wide", "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "width": 190, "type": "image", "legacy": {"wideheight": "126", "wide": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "widewidth": "190"}}, {"height": 447, "subtype": "xlarge", "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "width": 600, "type": "image", "legacy": {"xlarge": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "xlargeheight": "447", "xlargewidth": "600"}}, {"height": 75, "subtype": "thumbnail", "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "width": 75, "type": "image", "legacy": {"thumbnail": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}}], "byline": {"original": "By MATTHEW GOLDSTEIN", "person": [{"organization": "", "firstname": "Matthew", "lastname": "GOLDSTEIN", "rank": 1, "role": "reported"}], "contributor": "Andrew Pollack contributed reporting."}, "lead_paragraph": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "abstract": "Turing Pharmaceuticals founder Martin Shkreli is served subpoena to appear before House Committee on Oversight and Government Reform to discuss pricing trends and other developments in drug industry; it is unclear whether Shkreli, who has been charged with securities fraud, will show up to testify.", "keywords": [{"is_major": "Y", "rank": "1", "name": "organizations", "value": "Turing Pharmaceuticals AG"}, {"is_major": "Y", "rank": "2", "name": "persons", "value": "Shkreli, Martin (1983- )"}, {"is_major": "Y", "rank": "3", "name": "subject", "value": "Drugs (Pharmaceuticals)"}, {"is_major": "N", "rank": "4", "name": "organizations", "value": "House Committee on Oversight and Government Reform"}, {"is_major": "N", "rank": "5", "name": "subject", "value": "Prices (Fares, Fees and Rates)"}, {"is_major": "N", "rank": "6", "name": "subject", "value": "Securities and Commodities Violations"}], "section_name": "Business Day", "blog": [], "_id": "569fe66a38f0d80627b20ab9", "slideshow_credits": null, "pub_date": "2016-01-21T00:00:00Z", "type_of_material": "News", "print_page": "2", "subsection_name": "DealBook", "source": "The New York Times", "word_count": "848", "document_type": "article", "news_desk": "Business", "headline": {"print_headline": "Congress Calls Shkreli to Testify on Rapid Rises in Drug Pricing", "main": "Congress Calls Martin Shkreli to Testify on Rapid Rises in Drug Pricing"}}